Whipplewood Advisors LLC Has $106,000 Stake in Amgen Inc. $AMGN

Whipplewood Advisors LLC decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 64.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 381 shares of the medical research company’s stock after selling 685 shares during the period. Whipplewood Advisors LLC’s holdings in Amgen were worth $106,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. MQS Management LLC bought a new stake in Amgen during the second quarter valued at about $202,000. Linden Thomas Advisory Services LLC boosted its holdings in Amgen by 4.2% during the second quarter. Linden Thomas Advisory Services LLC now owns 7,415 shares of the medical research company’s stock valued at $2,070,000 after acquiring an additional 300 shares during the period. Leavell Investment Management Inc. boosted its holdings in Amgen by 0.9% during the second quarter. Leavell Investment Management Inc. now owns 18,224 shares of the medical research company’s stock valued at $5,088,000 after acquiring an additional 160 shares during the period. Brian Low Financial Group LLC bought a new stake in Amgen during the second quarter valued at about $310,000. Finally, B & T Capital Management DBA Alpha Capital Management boosted its holdings in Amgen by 3.5% during the second quarter. B & T Capital Management DBA Alpha Capital Management now owns 15,037 shares of the medical research company’s stock valued at $4,198,000 after acquiring an additional 504 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 1,267 shares of the stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the transaction, the senior vice president owned 7,209 shares of the company’s stock, valued at $2,141,000.91. This represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.69% of the stock is owned by company insiders.

Amgen Stock Performance

NASDAQ:AMGN opened at $291.76 on Monday. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $335.88. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24. The firm has a market capitalization of $157.07 billion, a PE ratio of 23.86, a price-to-earnings-growth ratio of 2.61 and a beta of 0.49. The firm has a 50-day moving average price of $287.92 and a 200 day moving average price of $287.33.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The firm had revenue of $9.18 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same quarter in the prior year, the business posted $4.97 earnings per share. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 22nd were given a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend was Friday, August 22nd. Amgen’s dividend payout ratio is 77.84%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on AMGN shares. Piper Sandler upped their price target on shares of Amgen from $328.00 to $342.00 and gave the company an “overweight” rating in a report on Monday, August 25th. UBS Group decreased their price target on shares of Amgen from $326.00 to $317.00 and set a “neutral” rating for the company in a report on Wednesday, August 6th. Morgan Stanley upped their price objective on shares of Amgen from $330.00 to $333.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Raymond James Financial began coverage on shares of Amgen in a research report on Wednesday, September 3rd. They set a “market perform” rating for the company. Finally, Bank of America upped their price objective on shares of Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a research report on Friday, September 26th. Six research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $300.94.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.